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The use of yttrium in medical imaging
and therapy: historical background
and future perspectives
Ben J. Tickner, a Graeme J. Stasiuk, b Simon B. Duckett a and
Goran Angelovski *c
Yttrium is a chemically versatile rare earth element that finds use in a range of applications including
lasers and superconductors. In medicine, yttrium-based materials are used in medical lasers and
biomedical implants. This is extended through the array of available yttrium isotopes to enable roles for
90Y complexes as radiopharmaceuticals and 86Y tracers for positron emission tomography (PET) imaging.
The naturally abundant isotope 89Y is proving to be suitable for nuclear magnetic resonance
investigations, where initial reports in the emerging field of hyperpolarised magnetic resonance imaging
(MRI) are promising. In this review we explore the coordination and radiochemical properties of
yttrium, and its role in drugs for radiotherapy, PET imaging agents and perspectives for applications in
hyperpolarised MRI.
Key learning points
1. Versatility of yttrium coordination chemistry results in a vast number of complexes with variable physicochemical features.
2. The properties of a range of yttrium isotopes enable their use in radiochemistry.
3. Yttrium radioisotopes exploited for medical imaging and radiotherapy applications.
4. Suitability of yttrium for NMR investigations and new perspectives for yttrium-based hyperpolarized MRI.
Introduction
Since its discovery in the late 18th century, yttrium has been
used as a material in lasers, superconductors, electrodes, and
LEDs. The wide range of applications of yttrium-based materials
has now extended into a variety of medical applications. As early
as the 1960s, there were reports of using yttrium-doped lasers
to remove lesions and 90Y-labelled microspheres for radio-
embolisation. Since then, the use of 90Y-based materials for
therapy has increased and they are now used clinically to treat
a range of diseases including Cushing’s disease, acromegaly,
haemophilia and a wide range of cancers. Rapid technological
advances have given additional momentum to its use in various
medicinal diagnostic and therapeutic methods. Imaging techniques
especially have benefited, giving rise to the development of
methodologies for the early stage detection of disease or early
treatment response. Developments in the chemistry of yttrium
have contributed significantly to this progress, providing valu-
able solutions through the preparation of contrast agents for
different imaging modalities, or radiochemicals and other
materials as therapeutics. Indeed, there are not many elements,
especially not metal ions, which feature in the production of
imaging agents or therapeutics as extensively as yttrium. Owing
to the existence of various isotopes, yttrium and its complexes
have found use in a wide range of diagnostics and therapy
applications in different medical methodologies. The versatility
of yttrium isotopes, which include 86Y and 90Y, has allowed for
PET and radiotherapy, respectively, underpinned by significant
research efforts and consequent reports over the past three
decades. Very recently, 89Y and its complexes have received
noteworthy attention in an emerging field of HP-MRI, a metho-
dology which has now been proven able to track real-time
metabolism in vivo. In turn, yttrium has shown to be an excellent
platform for the preparation of diverse agents that can be used for
multiple medical purposes. In this review, we aim to provide a
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brief historical overview of the role of yttrium in therapy and
medical imaging applications, anticipating possible advances in
the years to come.
Coordination properties of yttrium
The element yttrium has atomic number 39 and is grouped as a
transition metal in the periodic table, with electronic configu-
ration Kr4d15s2. It exists naturally as the 89Y isotope in 100%
abundance, and has a nuclear spin quantum number I of 1/2
which means it can produce very narrow peaks in corres-
ponding 89Y NMR spectra.
Yttrium has often been regarded as a rare earth element
because it bears little chemical similarity to its counterparts in
the d-block. Namely, while it can form metal carbon bonds
(various organoyttrium species have been reported),1 its chemistry
is most similar to that of the lanthanide elements. The main
reason for this behaviour is the phenomenon called the
lanthanide contraction, a result of poor shielding of nuclear
charge by 4f electrons throughout elements in the lanthanide
series (their general electronic configuration is Xe4fn5dm6s2,
where n = 1–14 and m = 0–1).2 Consequently, both yttrium and
the lanthanides do not exhibit the common properties of the
transition metals; in fact, by strongly resembling the chemical
properties of the lanthanides, yttrium itself is often regarded as
a member of this series.
Some of the properties valid for yttrium and other members
of this series are:
 Their overall level of reactivity is greater than that of
transition metals, being instead more similar to the group 2
elements.
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 They exhibit a wide range of coordination numbers.
 They form labile ionic complexes, which are prone to the
facile exchange of ligands.
 Their hydroxides are insoluble at neutral pH.
 Their coordination properties are determined by the steric
factors of ligands rather than crystal-field effects.
 They prefer oxidation state +3.
 They have a preference for anionic ligands with donor
atoms of rather high electronegativity.
The oxidation state +3 is the most common for yttrium,
although oxidation states of 0, +1 and +2 have been reported.3,4
Due to the above mentioned chemical properties, yttrium can
exist in a number of complexes in which the central Y3+ ion can
assume an array of different CN of up to 9 within the inner
sphere. In this review, we will not cover all of the different types
of complexes that can be made with yttrium, as this topic has
been well explored in previous reviews and book chapters.2,5,6
Here, we will briefly mention its complexes with the most
commonly used classes of multidentate ligands as the resulting
products exhibit high stability, which makes them suitable for
medical applications.
Common ligands used for coordination
to yttrium
Yttrium and its analogous lanthanide ions exhibit toxicity
in vivo.7 For this reason, it is important to ensure that complexes
exhibit high thermodynamic stability, as well as being kinetically
inert. This behaviour can be achieved by using multidentate
ligands (Fig. 1), usually polyaminocarboxylic acids such as EDTA,
DTPA, DO3A and DOTA (all abbreviations used are defined in the
notes and references section at the end of the manuscript). It is
important to consider ligand denticity and the chelate formation/
dissociation kinetics when anticipating applications for these
chelated systems. For instance, all of these ligands rapidly form
complexes, which is particularly important for the production of
radiopharmaceuticals. However, hexadentate EDTA complexes
have neither sufficient thermodynamic stability nor the inertness
required for medical utilisation. On the other hand, both octa-
dentate DTPA and DOTA complexes exhibit high thermodynamic
stability and their derivatives are widely used for the production of
radiopharmaceuticals (see below).8,9 Still, one should note that
macrocyclic complexes based on the DOTA ligand have consider-
ably higher thermodynamic stability than those based on the
acyclic DTPA (Table 1). Namely, logK values for Y-EDTA and
Y-DTPA are found to increase from 18.5 to 22.5 due to a change
in denticity of the chelating ligand from 6 to 8. logK increases
further to 24.3 when DOTA, an octadentate macrocyclic ligand, is
employed. However, the stability is lower if the complex with the
heptadentate macrocyclic ligand DO3A is formed (logK = 21.1).
Similarly, the kinetic stability of the complexes formed with
macrocyclic ligands is significantly higher than those of their
acyclic counterparts. In a recent study, the acid-assisted disso-
ciation of Y-DOTA and Gd-DOTA complexes was followed in 2 M
and 4 M HCl by HILIC and ICP-MS.10 The obtained half-life was
639 min and 312 min in 2 M HCl for the Y-DOTA or Gd-DOTA
complexes respectively, while these values dropped to 230 min
and 88 min respectively in 4 M HCl. These values are commen-
surate with high stability in harsh conditions. In parallel, the
studied acyclic complexes show a lack of stability at less acidic
conditions compared to the macrocyclic complexes. Specifi-
cally, at pH 6 and in the presence of an excess of competing
cation (Zn2+), these complexes undergo dissociation, resulting
in half-lives of 47 min and 96 min in the presence of 5 mM Zn2+
for Y-DTPA and Gd-DTPA respectively, which reduced to 20 min
and 52 min in the presence of 10 mM Zn2+.
Fig. 1 Common ligands reported for chelation to yttrium that are discussed in this work.
Table 1 Thermodynamic stability constants of Y3+ complexes with EDTA,
DTPA, DO3A and DOTA. Values for analogous Gd3+ complexes are
provided for better comparison of propertiesa





a logK is the logarithm of the formation constant. Values taken from
ref. 9.
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The stability of these metal ion complexes can be increased
by synthesising analogues with greater backbone rigidity.11 For
example, CHX-A00-DTPA is a common derivative of DTPA that
contains a rigid cyclohexane group in the DTPA backbone
resulting in an increase in logK from 22.5 to 24.7 for Y-DTPA
and Y-CHX-A00-DTPA respectively.12
The geometry of the Y3+ complex is also affected by CN and
ligand denticity. Complexes based on octadentate DOTA or
DTPA typically adopt CN of 9 with an inner sphere water
molecule providing an additional donor site. These coordination
geometries can span distorted dodecahedron, TTP and SAP/TSAP
for Y-EDTA, Y-DTPA and Y-DOTA complexes, respectively.2,9
TTP geometries contain ligand donor atoms arranged in triangles
in three different planes, whereas SAP and TSAP isomers contain
donor sites oriented in rectangles in two different planes with an
additional ligand (usually water) occupying a ‘capped’ position
(Fig. 2a). SAP and TSAP geometries are distinguished based on the
angle between the two planes of donor ligands, which is typically
smaller in TSAP structures. Information on these geometries
comes most readily from X-ray crystal structures (Fig. 2b).9,13,14
Moreover, the presence of nitrogen donor atoms, and the different
binding conformations exhibited by these polyaminocarboxylate
ligands results in formation of multiple product isomers
which can often interconvert at room temperature.8 For DTPA
Fig. 2 (a) Representative TTP, SAP and TSAP geometries. In SAP geometries the angle of rotation between the two planes is larger than that in TSAP
isomers (b) X-ray crystal structures of a range of yttrium complexes: examples of a yttrium cyclen derived complex with CN = 8 (upper left),13 Y-DTPA-
derived complex with CN = 9 adopting a TTP structure (upper right)14 and a Y-DOTA derivative existing in both TSAP (lower left) and SAP (lower right)
geometries in the same unit cell.9 The coordinated water molecule in the latter three examples is partially obscured by the central yttrium atom. Note that
all solvent of crystallisation, counterions and non-hydrogen atoms have been removed for visual clarity. Thermal ellipsoids are shown with 50%
probability for those examples with atomic displacement parameters available from the crystallographic database. Otherwise, structures are shown as a
ball and stick model.
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complexes, eight such isomers exist with the TTP geometry, which
can interconvert through nitrogen inversion.15 On the other hand,
macrocycle formation reduces the degrees of freedom exhibited in
DOTA complexes, thus resulting in four possible isomers that
assume the above mentioned SAP and TSAP structures. The latter
present more restricted coordination environments, which often
result in longer distances between the metal ion and any coordi-
nated water molecules.9 Consequently, isomers existing in a TSAP
geometry exhibit faster water exchange rates.8 In other words, the
size and steric congestion of the central metal ion and groups
attached to the DOTA ligand influence the isomers formed, which
affects both the NMR and MRI properties of the desired com-
plexes. These multiple species often display quite complex spectra
in corresponding 1H NMR measurements provided isomer
exchange is slow on the NMR timescale. However, low tempera-
ture NMR studies have been used to slow dynamic behaviour and
investigate such isomers in solution.15
The ability of DOTA and CHX-A00-DTPA to form stable com-
plexes with yttrium has led to their widespread use in radio-
pharmaceutical applications. In fact, of all the reported
examples of yttrium containing radio drugs or imaging agents
(see below), the significant majority are based on DOTA or
CHX-A00-DTPA. Despite this, many researchers are developing
new ligands that form stable yttrium complexes with fast
radiolabelling conditions. These are typically based on PCTA,
DEPA, OCTAPA or NETA ligands (Fig. 1).12 A number of
derivatives, variations, and combinations of these common
ligand scaffolds are possible, although a full account of
all ligands reported for coordination to yttrium is beyond
the scope of this manuscript and has been addressed
previously.2,5,6,16 The stability or inertness of these complexes
is typically determined by reference to a range of measures
including thermodynamic (logK)9 and kinetic (k)17 complex
formation constants, dissociation half-lives (i)10 or pM
values,16 which have been described for these and related
ligands elsewhere. Beside optimising their stability to match
the desired metal ion, these molecules are further developed to
serve as so-called bifunctional chelators. Such systems concur-
rently chelate the metal, while also possessing functional
groups that allow further functionalization to e.g. targeting
vectors, resulting in a target specific tracer or therapeutic drug
(see below).16
Considering the similarities in coordination chemistry
between lanthanides and yttrium, the general properties of
these ions listed previously should be noted for different
potential medical imaging and therapy applications of yttrium.
Principally, selecting the ligands with sufficient thermo-
dynamic stability, fast complex formation kinetics and good
inertness is sufficient if anticipating the use of yttrium com-
plexes for preparation of radiopharmaceuticals. Nevertheless,
the coordination chemistry of the Y3+ complex must also be
considered if the purpose is MRI application. Namely, it is well
known that highly paramagnetic Gd3+ is routinely used as a
MRI contrast agent in its chelated forms with DTPA-, DO3A- or
DOTA-type ligands.8 Due to similar ionic radii (90.0 pm
and 93.8 pm for Y3+ and Gd3+ respectively), many studies have
replaced gadolinium by yttrium and investigated the coor-
dination properties of the resulting complexes by means of
1H NMR.17 However, the most recent applications of yttrium
complexes in 89Y NMR combined with hyperpolarisation (see
below) mean a more detailed consideration of its coordination
properties is warranted.
Radiochemical properties and
production of yttrium isotopes
Yttrium is found in many rare earth minerals rather than as the
free element and is much more common in the earth’s crust
than many of the transition metals such as gold and silver.
It was first isolated in its elemental form in 1828 and is now
commonly obtained from its ores by dissolution in sulphuric
acid and fractionation of the different metal ions by ion
exchange chromatography. Subsequent addition of oxalic acid
allows for the isolation of yttrium oxalate precipitates. From
this, oxidation can yield yttrium oxide while further reaction
with hydrogen halides yield yttrium halide salts.2 In 2014,
around 7000 tonnes of yttrium oxide were produced each year,
most of this by China. Yttrium is found in one naturally
occurring isotope: 89Y, although other isotopes including 90Y
and 91Y are found as waste products from uranium fission.
While 89Y is found in many rare-earth minerals and can be
found in trace amounts in living systems, it has no known role
in biological processes. Studies on the toxicology of 89YCl3 in
rats showed an increase in blood calcium concentration upon
yttrium addition suggesting the replacement of calcium in
bone by yttrium.7 Calcium deposits in the liver and spleen
suggest these organs are the primary targets of intravenously
injected yttrium.
Currently, no fewer than 34 radionuclides of yttrium, from
76Y to 109Y, have been synthesized and observed.18 While 86Y,
87Y, 88Y, 90Y and 91Y have half-lives of 14.7 hours, 79.8 hours,
106.6 days, 64.1 hours, and 58.5 days respectively, all other
yttrium isotopes (excluding the naturally abundant 89Y) are
much shorter lived with half-lives of less than a few hours.
The main isotopes of yttrium can be grouped into two types
depending on their main decay processes (b or b+) and their
half-lives (Table 2).
The neutron rich isotopes (90Y and above) decay predomi-
nantly via b decay (electron emission) in which a neutron is
converted into a proton releasing an electron and an anti-
neutrino to form zirconium species. The kinetic energy released
from rapid deceleration of these high energy electrons through
interaction with surrounding matter produces radiation, which
can be converted into photons. Alternatively, decay of those
proton rich isotopes (88Y and below) can occur via b+ decay
(positron emission), in which protons convert into neutrons
releasing a positron and a neutrino to form strontium species.
Those radioisotopes that exhibit b+ decay can be used for PET
imaging, which typically includes isotopes such as 11C, 13N,
15O, 18F, 68Ga or 89Zr.
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90Y is a good candidate for radiotherapy as it releases
high energy b particles that have strong penetration of the
surrounding tissues (11 mm).12 These particles can affect cell
viability by causing direct damage to the structure of DNA, or
they can cause indirect cell death by increasing the concen-
tration of toxic free radicals present in cells.6 The conjugation
of such radioisotopes to antibodies or other cancer directing
groups help restrict secondary damage and focus the benefits
to areas of cancer; this forms the basis of radiopharmaceuticals
which are discussed later.
Many radioactive yttrium isotopes have important medical
uses with 86Y being used for PET imaging and 90Y for radio-
therapeutics. The synthesis, separation, and isolation of these
isotopes is clearly very important. A summary of the first report
of each synthetic yttrium isotope, and its initial synthesis, is
given by Nystrom et al.18 Briefly, 90Y isotopes were first made in
1937 from high energy neutron bombardment of 89Y, although
separation of 90Y from 89Y is extremely challenging. For in vivo
applications, 90Y is now more commonly made from 90Sr, one
of the waste products from the fission of 235U (Scheme 1).6,19
For medical applications, it is important that 90Y can be
synthesised free from its parent 90Sr isotope. 90Sr displays
similar behaviour to calcium and is also known to be deposited
in bone causing a range of health concerns including leukaemia
and bone cancers. Separation of this toxic precursor is there-
fore essential for any use of 90Y as an in vivo probe. Methods
were developed to separate these two ions as early as the
1950s, using ion exchange principles to exploit the different
charges and preferred oxidation states of strontium and
yttrium salts.19
Lighter radioactive isotopes of yttrium including 86Y and 88Y
are often produced by neutron bombardment of 89Y.18,20 There
are three main precursors used for the synthesis of isotopes
such as 86Y, which include enriched 86Sr, 88Sr, and natural Rb
(Scheme 2). Bombardment of Rb with alpha particles to form
86Y and the (p,3n) reaction in which 88Sr nuclei absorb a proton
and release 3 neutrons are not commonly used due to the
high 30–55 keV energies of the alpha particle (a) or protons
necessary. These energies are higher than those that can be
produced in small synchrotrons.20 Commonly, the (p,n) reac-
tion from an enriched 86Sr precursor is used due to the high
purity of the resulting 86Y.20 Bombardment of a typical 86SrCO3
target in the presence of HCl, NH4OH, H2O, and La
3+ yields
mixtures containing 86Y(OH)3, which are typically separated
using centrifugation and ion exchange chromatography.
Subsequent addition of a-hydroxybutyrate and heating yields
carrier-free 86Y.20 Alternatively, separation of Sr(OH)3 and
Y(OH)3 can occur via electrochemical methods.
20
Similar isotopes including 88Y can also be produced by
irradiation of a SrCl2 target and subsequent separation using
a cation exchange resin. These separation techniques are highly
effective and can give batch yields of 3.5 GBq and 35 MBq for
86Y and 88Y respectively with low impurities (o3% 87Y and
o0.01 ppm Sr).20 The production of many different yttrium
isotopes using cyclotron-based approaches, and their separa-
tion is an active area of research.
Yttrium-containing materials for
medical purposes
Yttrium has a wide range of medical uses including as radio-
pharmaceuticals, lasers, and implant coatings. A range of
Table 2 Half-lives and main decay processes for the most common yttrium isotopes. Those radionuclides ranging from 76Y to 84Y and 94Y to 109Y are
omitted due to half-lives shorter than a few minutes
Isotope Abundance Half live Main decay process Main decay product Applications Ref.
85Y Synthetic 2.7 hours b+ 85Sr N/A 18
86Y Synthetic 14.7 hours b+ 86Sr PET 18 and 20
87Y Synthetic 3.4 days b+ 87Sr PET 18 and 20
88Y Synthetic 106.6 days b+ 88Sr PET 18 and 20
89Y Natural Stable N/A N/A Lasers, HP-MRI 18
90Y Synthetic 2.7 days b 90Zr Radiotherapeutics 18 and 19
91Y Synthetic 58.5 days b 91Zr N/A 18
92Y Synthetic 3.5 hours b 92Zr N/A 18
93Y Synthetic 10.2 hours b 93Zr N/A 18
Scheme 1 Radiochemical reaction showing 90Y formation from its parent
90Sr isotope and its decay into stable 90Zr.
Scheme 2 Routes that lead to the formation of 86Y isotopes.
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yttrium containing materials including yttrium fluoride nano-
particles have antibacterial properties and can be used to
reduce bacterial colonisation of implanted surfaces.21 The use
of yttrium stabilised zirconia as materials for dental implants
has also been reported (Fig. 3a).22 Here, yttrium finds use in
stabilising cubic polymorphs of zirconia which are usually
unstable because of the large changes in volume that result
upon moving between different polymorphs. This is prevented
by substitution of Y3+ into the crystal lattice of the smaller
Zr4+ ion to produce doped zirconia that is stable over a wider
temperature range.22
The addition of yttrium to enhance material properties is
also observed in the operation of neodymium doped yttrium
aluminium garnets (Nd:YAG), which were first demonstrated in
1964 and have since been used to treat a wide range of medical
ailments.23 Nd:YAG lasers emitting light at 1064 nm are most
commonly used for thermotherapy, in which lesions can be
removed from a surface through laser ablation.23 Lasers of this
type can cut tissue with high precision, without causing
thermal damage to the surrounding areas due to the absorption
of laser light by water in nearby tissues. In the 1980s, bladder,
penile, and oesophageal tumours were treated with endoscopic
laser therapy and the range of cancers treated using this
approach has increased since then.23 Such lasers are also used
in minor cosmetic procedures ranging from laser hair removal
and wart removal to liposuction.
Other yttrium based therapies have been developed that
rely not on the addition of naturally occurring 89Y to enhance
the properties of materials such as lasers or ceramic coatings,
but rather to exploit the radiochemical properties of radio-
active 90Y in materials or complexes. Some of the earliest uses
of 90Y agents include its incorporation into microspheres
for radioembolisation, which has been used clinically since
the 1960s. Radioembolisation is a non-invasive method used
to treat cancers or internal bleeding, in which a radionuclide
in a microsphere is used both to block blood delivery to a
site of cancer, and to deliver the b radiation necessary to
promote cancer cell death. This is commonly used to treat
unresectable cancers (which cannot be completely removed by
surgery), in organs such as the liver and involves injection
of the microspheres into the hepatic artery.24 Currently,
microspheres are made from either glass24 or resin (Fig. 3b
and c).22,25 The diameter and therefore the properties and
radioactive doses of these microspheres can be altered to
achieve the desired properties. Commonly, these micro-
spheres are synthesised via sol–gel chemistry or spraying
techniques to achieve beads containing yttrium oxides of a
desired diameter.25 Subsequent neutron bombardment yields
the radionuclide 90Y.
90Y can be incorporated into a range of other materials
including needles and rods. 90Y rods have been implanted into
the pituitary gland in order to treat Cushing’s disease.26 This
disease results from heightened levels of the hormone cortisol
caused usually by steroid overuse or adrenal or pituitary
tumours. Implantation of 90Y can have therapeutic effects on
such pituitary tumours26 and reduce the effects of acromegaly,
a hormonal condition caused by excess production of growth
hormone by the pituitary gland.27 Other 90Y containing materi-
als such as 90Y needles have been used for synvectomy. This
technique removes synovial tissues around joints which often
become inflamed in conditions like rheumatoid arthritis. This
inflamed tissue can be removed surgically or by using drugs or
radiotherapeutics such as 90Y to reduce the mass of inflamed
tissue.28 Injection of 90Y into joints of haemophilia patients has
been found to induce fibrosis and reduce internal bleeding in
joints.29 Such treatments have previously used radioactive
isotopes such as 198Au, although isotopes including 90Y, 186Re
and 169Er are preferred. Agents such as 90Y silicate have a
particle size of 0.1 mm which is around 50 times larger than
those of the previously used colloidal 198Au system which
prevents unwanted spread of the agent to other sites via the
lymphatic system.29
Fig. 3 The use of yttrium in materials for medical purposes. (a) Radiographic control of a yttrium stabilised zirconia dental implant 24 months after
surgery. Reproduced with permission from ref. 22. Copyright r 2012, Medicina Oral S. L. (b) and (c) Examples of typical scanning electron microscope
(SEM) images of yttrium-containing microspheres. Reproduced with permission from ref. 25. Copyright r 2014, Springer Nature.
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Yttrium-containing complexes for
therapy
Clinically approved radioagents based on 90Y have been used
for the treatment of various types of cancers. These are based
on the conjugation of 90Y chelators such as DTPA or DOTA to
cell receptor targeting motifs (peptides/antibodies) to direct the
therapy to the cancer cells. For example, the conjugation of
DTPA or DOTA to different peptides has been used to target the
chelate ions to different sites in the body. Similarly, Gd3+
complexes based on DOTA and its analogues have been con-
jugated to peptides for use as targeted MRI contrast agents. 86Y
complexes have been used to image the biodistribution and
uptake of the analogous Gd3+ or 90Y complex (see below).10
Several excellent reviews on some of these agents, and the
clinical studies that have been performed, exist.5,6 Hence, here
we provide only a general overview of the different types of
90Y-radiopharmeceuticals and how they work.
There are several key factors in the selection of a chelator
with targeting peptide/antibody for effective therapy:
 Radiolabelling conditions for the chelator.
 Kinetic/thermodynamic stability of the complex.
 Radiation half-life compared to biological half-life.
Radiolabelling conditions for 90Y complexes vary with the
choice of chelator. DOTA-based chelators all use conditions
between pH 4.5 to 6, with heating as high as 100 1C for
15 minutes to form stable complexes (Tables 3 and 4), with a
high molecular activity (45–75 GBq mmol1). These harsh
conditions are tolerated by small peptide targeting vectors,
indicated by the use of DOTA in somatostatin radiotherapy
(discussed below). DTPA has been shown to be labelled with 90Y
at room temperature at pH 5.5 between 5–30 minutes, giving
molecular activities of around 781 MBq mg1. The resulting
complex shows sufficient stability to be utilised in vivo. The key
here is that the complex is formed at room temperature, so it
can be used for antibody labelling, which is more sensitive to
elevated temperatures. The half-life of 90Y is 2.7 days (Table 2),
which is consistent with the biological half-life of antibodies;
therefore, DTPA is more suited for conjugation to antibodies
and radiolabelling with 90Y.
90Y based small molecule agents utilising the coordination
chemistry properties of yttrium, rather than its incorporation
into bulk materials, have been developed to deliver the b
radiotherapy to a specific cell type. Cancerous cells are known
Table 3 Summary of selected 90Y radiotherapeuticsa
Name Chelator Bioconjugate Target Labelling conditions Dose Disease Studies Ref.






100–150 000 rad Cushing’s disease 26
— Acromegaly 27








Somatostatin 0.4 M NH4OAc or
0.2 M NaOAc
pH 5 90 1C 25 min30





90Y-DOTALAN DOTA lanreotide 30 and
32
90Y-DOTANOC DOTA 1-NaI3-octreotide 33
90Y-DOTAOC DOTA Octreotide 33
90Y-SMT487 DOTA DPhe1-Tyr3-
octreotide
— — Primates 35
90Y-Citrate Citrate N/A N/A — 1 MBq Prostate cancer
(bone metastases)
Human 35














DTPA Trastuzumab HER2 0.2 M NH4OAc
pH 5.5 37 1C 1 hour








NETA Trastuzumab 0.25 M NH4OAc
pH 5.5 RT 5 min
— Breast cancer Mice 12









a Any abbreviations used are defined in the notes and references section at the end of the manuscript.
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to overexpress receptors on their cell surfaces for a wide range
of different proteins. This has formed the basis of drug and
peptide receptor radionuclide therapy (PRRT). One such over-
expressed receptor is that for somatostatin, a growth hormone-
inhibiting hormone, which inhibits the release of a range of
hormones including insulin and glucagon via its interaction
with G-coupled protein receptors.30 Conjugation of radionu-
clides to somatostatin analogues allow for incorporation of the
agent into the cancerous cell, localising b emission in the area
of cancer. Somatostatin was an important synthetic target for
many years and many groups used solid phase approaches to
synthesise this natural product. A more potent somatostatin
analogue called octreotide was first synthesised in 1979 and
derivatives have since been conjugated to 90Y coordinating
motifs such as DTPA and DOTA derivatives. Currently,
90Y-DOTATOC is the most commonly reported 90Y radiotherapy
that targets somatostatin receptors (Fig. 4).30 It has commonly
been used to treat tumours of the endocrine or nervous systems
although other cancers such as glioma and meningioma have
also been targeted.30 Similar systems such as 90Y-DOTATATE,31
90Y-DOTALAN,32 and 90Y-DOTANOC33 have also been reported,
which involve the conjugation of 90Y to other octreotide-like
peptides that target somatostatin receptors. The selection of
either the chelator or the final charge of the complex can alter
the biodistribution of the therapeutic agent (or imaging agent,
see later), resulting in different levels of accumulation in
target sites.
Fig. 4 90Y complexes for targeted therapy. Conjugates of 90Y and its
macrocyclic chelator DOTA (black) with an octreotide-like peptide (blue)
can bind to over expressed somatostatin receptors on cancer cell surface
membranes. Upon transport into the cancerous cell, the emitted b radiation
has therapeutic effects.
Table 4 Summary of selected 86Y and 87Y radiotracers used for PET imaginga
Name Chelator Bioconjugate Target Labeling conditions Dose Disease Studies Ref.




86Y-DTPA DTPA N/A N/A Citrate buffer
pH 6 80 1C 5 min
11.8–14.7 MBq — Rats 10
86Y-DOTA DOTA N/A N/A Citrate buffer
pH 6 80 1C, 30 min
11.8–14.7 MBq — Rats 10






Somatostatin — 10–40 MBq Neuroendocrine
tumours
Primates 35
86Y-DOTATOC DOTA DPhe1-Tyr3 -
octreotide
0.15 M NH4OAC




















— — Melanoma Mice 44
86Y-MP2346 DOTA MP2346 Gastrin releasing
peptide receptor





Cetuximab HER1 receptors 0.1 M NH4OAC
pH 5–6 RT
30–60 min
































Bevacizumab VEGF-A 0.15 M NH4OAC





87Y-EDTMP EDTMP N/A N/A — 2 MBq — Mice 49
a Any abbreviations used are defined in the notes and references section at the end of the manuscript.
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It must be stated that there has been a switch in the clinic
towards 177Lu in PRRT, which is due to the b range decreasing
from 11 mm to 2 mm, thus reducing non-specific cross fire side
effects.12 This move has also brought the use of combination
therapy, using both 90Y-DOTATATE and 177Lu-DOTATATE,
which aid these dosimetry calculations, although this matched
pair has advantages compared to using just 90Y-DOTATATE.31
The same is valid for the 90Y-DOTATOC analogue.34
An accurate prediction of the radiation dose provided by
exposure to these 90Y agents is challenging. In the 1990s
analogous 111In agents were used although this isotope is
now rarely deployed due to differences in the biochemical
behaviours of 90Y and 111In that have since been observed.12
Attempts to reduce the dose administered (3.7 GBq m2) of 90Y
PRRT, have resulted in the match pair isotope 86Y being more
commonly used to map where the therapy will go in vivo via PET
(see below). This allows clinicians to monitor in each patient
where the somatostatin positive tumours and the non-specific
localisation of the tracers are, such that an appropriate dose of
90Y can be adminstered.35
In recent years, many other over expressed surface receptors
on cancer cells have been targeted for radiotherapy with 90Y
complexes. Many lymphomas express specific antigens (CD20)
that are not expressed on normal cell surfaces. This provides
a route for targeted radiotherapy in which radionuclides
are attached to antibodies specific to cancer cells. Since the
development of 90Y-DOTATOC, antibody conjugates such as
90Y-ibritumomab tiuxetan (Zevalin) have been developed for
this purpose, consisting of a 90Y coordinating group (tiuxetan)
and the anti-CD20 antibody ibritumomab (Fig. 5a).36 In addi-
tion to 90Y loaded microspheres and 90Y-DOTATOC, Zevalin has
also received FDA approval for human use (in 2002) and has
been shown to improve survival rates in patients (over a 7 year
period).36
Over recent years many other antibody based 90Y therapies
have been developed involving cetuximab,37 panitumumab,38
trastuzumab39 and rituximab.40 While rituximab also targets
CD20, other therapies have targeted receptors such as EGFR
(cetuximab and panitumumab) or HER2 (trastuzumab)
(Table 3). This is largely due to the matching half-life of
90Y (2.7 days) and the biological half-life of antibodies.39 Such
agents are typically used to treat non-Hodgkin lymphoma,
a group of blood cancers that develop from white blood
cells. The conjugation of panitumumab to a 90Y-DOTA or
90Y-DTPA based group has been used to treat head and neck
cancers in a mouse model.38 The related cetuximab is able
to cross the blood brain barrier. Upon the administration of
90Y labelled cetuximab, accumulation in brain tumours was
observed and studies have investigated its effect on human
cancer cell lines.37 90Y radiolabelling was found not to affect
the action of cetuximab. Radiotherapy using 90Y labelled
rituximab has yielded complete metabolic remission for
patients with Nodular lymphocyte-predominant Hodgkin
lymphoma40 (Fig. 5b and c) and the use of new 90Y labelled
antibody conjugates of this type, and others, are expected to
increase in the future.
PET imaging using yttrium-based
tracers
Imaging techniques such as PET can take advantage of those
radionuclides that exhibit b+ decay. The production of high
energy positrons during this decay can be detected indirectly
through the production of two gamma photons formed from
annihilation of positrons with surrounding electrons in tissues.
This annihilation of antiparticles will occur when the high
Fig. 5 Applications of 90Y labelled antibody-based therapy. (a) Depiction
of Zevalin, a conjugate of anti-CD20 antibody ibritumomab and the DTPA-
derived 90Y chelator tiuxetan. (b) and (c) Example of 18FDG PET/CT sagittal
slices showing retroperitoneal lymph nodes (yellow arrows) of a 38 year
old male patient with nodular lymphocyte-predominant Hodgkin lym-
phoma (b) before and (c) 6 months after treatment with 90Y-rituximab
radioimmunotherapy. Adapted with permission from ref. 40. Copyright r
2018 John Wiley & Sons A/S.
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energy positrons have travelled from the source of the radio-
tracer and have lost sufficient kinetic energy to interact with
surrounding electrons. Encounters between positron and elec-
tron will produce two gamma photons moving in opposite
directions. These are distinguished from background photons
by detecting photon pairs arriving at a camera placed around
the patient within short time intervals. The most common
radiolabelled probe used clinically is 18F-fluorodeoxyglucose
(18FDG), which allows glucose uptake to be imaged using
PET.41
Imaging the uptake and biodistribution of 90Y agents is very
important in determining the dosage and side effects of such
therapies. Dual therapies in which injected agents have the
therapeutic effects of 90Y based agents whilst retaining the
potential to be simultaneously imaged inside the body are
clearly essential. Imaging 90Y is a challenge and there have
been many attempts to address this including imaging the
Bremsstrahlung radiation emitted from the b+ decay of 90Y.5
While 90Y decays predominantly by b+ processes, it has been
known since the 1950s that minor decay via positron emission
(34 ppm, 0.003%) is possible. In the past, the most common
approach has been to administer the same 90Y based agent
coordinated to a different radionuclide that undergoes positron
emission and can be imaged by PET. Co-administration of
other radionuclides such as 44Sc, 68Ga, 111In or 177Lu is com-
monly used as a route to image the progress, uptake, dosage, or
biodistribution of the analogous 90Y radiotherapeutic agent at
the target site or in off-site organs via PET or SPECT (isotope
dependent).31,34
It has recently been shown that 90Y distribution can be
quantified using direct positron emission from 90Y.42 This
imaging route faces challenges from low positron emission
and high background signals from Bremsstrahlung radiation,
although despite this it can give some route to imaging 90Y
distribution.42 Direct imaging of 90Y via either Bremsstrahlung
radiation or b+ decay is feasible. For instance, combined
Bremsstrahlung SPECT and 90Y PET/CT imaging of 90Y labelled
microspheres was achieved by injecting them into an area of
metastatic cholangiocarcinoma in the left hepatic lobe (Fig. 6).43
A PET image using 18FDG is also included for comparative
purposes. Here, Bremsstrahlung SPECT imaging gives a diffuse
response in the area of the tumour while 90Y PET/CT gives a
more localised response.43 In this case there is poor uptake of
90Y agent into the tumour and signal is much more localised in
the cancerous target upon imaging with 18FDG.
Increasingly, those yttrium isotopes such as 86Y that do
decay predominantly via b+ emission (half-life 14.7 hours) are
being investigated as potential PET imaging agents.44 86Y is a
non-ideal isotope for PET imaging because 67% of its b+ decay
processes are accompanied by release of gamma rays. Simulta-
neous g ray emission can fall into the accepted energy window
of PET scanners (350–650 keV), which results in background
signals. Such background noise can lead to increased false
positive detection by the PET scanner and therefore erroneous
quantification of 86Y concentration.
Methods are being developed to apply background correc-
tions to 86Y PET images to help alleviate these interference
issues.45 Consequently, noise in PET images of 86Y-DOTATOC
can be reduced upon background subtraction (Fig. 7).45 In
comparison, decay from the more commonly used 18F isotope
consists of only b decay.
Despite these challenges, the most promising use for 86Y
radiotracers is in combination with 90Y radiotherapy analogues
as matched pair isotopes to predict the distribution and
dosimetry of subsequently injected radiotherapeutics in the
same way as other PET agents (i.e. 68Ga).46,47 In the case of
86Y/90Y mixed pairs, the biological distribution/pharmaco-
kinetics of the two isotopes will be identical as the chemical
properties of the PET tracer and the radiotherapeutic are the
same.48 This will give clinicians the ability to predict where the
treatment will go on a patient by patient basis. This means that
if there is significant off site organ uptake, the optimum
radioactivity dose can be given, which is expressed as max-
imum dose at target tissues versus tolerable dose at healthy
organs. The appropriate doses of the radiotherapeutic can be
given to lower the cross fire or side effects of the radiotherapy
and make it more effective as a therapeutic. The standard doses
of PET imaging agents administered to patients lies in the
Fig. 6 Use of 90Y for SPECT and PET imaging. 90Y labelled microspheres were injected into an area of metastatic cholangiocarcinoma in the left hepatic
lobe and the imaging was performed either using: (a) Bremsstrahlung SPECT, (b) 90Y PET/CT, or (c) 18F PET using 18FDG prior to radioembolisation.
Reproduced with permission from ref. 43. Copyright r 2014, Pasciak, Bourgeois, McKinney, Chang, Osborne, Acuff and Bradley.
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1–300 MBq range, while for therapeutic isotopes it is in the
6–32 GBq m2 range (Table 4). Typically, this results in a
picomolar concentration range of PET tracers required to give
these radiation doses. A similar approach has used PET ima-
ging of 86Y labelled analogues to predict the biodistribution
and clearance pathways of analogous gadolinium based MRI
contrast agents. It has been known that the use of Gd-based
contrast agents can be connected with the nephrogenic system
fibrosis disease, which is related to deposition of Gd3+ in the
kidneys of patients with poor renal clearance, or can lead to
deposits in the brain. In fact, it is extremely challenging to
measure the biodistribution of Gd-based agents, and
T1-weighted MRI is unable to measure residual concentrations
of this ion. To this end, PET imaging of 86Y-DTPA has been used
to track the clearance pathways of the analogous Gd-DTPA in
rats (Fig. 8).10 These images show that the injected agents
are predominantly excreted through the kidneys in less than
4 hours, although a small amount of agent is retained by the
kidneys and excreted over a longer time scale (images recorded
up to 48 hours post injection).10 PET images are even able to
show the presence of secondary excretion pathways. For exam-
ple, PET images acquired 4 hours post injection showed that
the agent was present in the large intestines suggesting that
hepatic clearance is also occurring (Fig. 8d).10 The use of 87Y
and 88Y as potential SPECT and PET tracers respectively has
also been investigated.49 In an attempt to show the broadness
of different 90Y- and 86Y-based radiotracers for medical imaging
and therapy, we have summarized their use along with the
chelators, type of bioconjugates, desired targets, labelling con-
ditions, dosages and specific applications (Tables 3 and 4).
Hyperpolarised 89Y complexes as MRI
probes
In contrast to PET, MRI uses magnetic field gradients and
radiofrequency pulses to produce spatially and temporally
resolved images of living systems. This technique involves the
use of non-ionising radiation and does not require specialist
facilities like those necessary for PET. Instead, it routinely
detects NMR-active nuclei, which in the majority of cases are
water protons, where different environments are distinguished
by their longitudinal (T1) or transverse (T2) relaxation time
constants.8 It is the low inherent sensitivity of MRI that
necessitates reliance on the bulk 1H2O signal to convey this
information. MR sensitivity is derived from small perturbations
in the population of states occupying closely spaced nuclear
spin energy levels in a magnetic field. While relaxation indu-
cing agents often provide a route to improving contrast, many
Fig. 7 Effect of background subtraction on 86Y PET imaging. PET imaging
of 86Y-DOTATOC with and without background subtraction. Reproduced
with permission from ref. 45. Copyright r 2003, Springer Nature.
Fig. 8 PET imaging of 86Y complexes as surrogates for Gd MRI contrast
agents. Example MRI, PET and overlaid PET/MRI images of rats taken (a)
5 min (b) 10 min (c) 1 h (d) 4 h (e) 24 h and (f) 48 h after the injection of
86Y-DTPA (11.8 MBq) and Gd-DTPA (0.6 mmol kg1). Note that the
intensity scale for (a)–(c) and (d)–(f) are not the same. Reproduced with
permission from ref. 10. Copyrightr 2019 Wiley-VCH Verlag GmbH & Co.
KGaA, Weinheim.
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researchers are turning their attention to hyperpolarisation as a
non-toxic alternative to address insensitivity.50
Hyperpolarisation techniques such as dynamic nuclear
polarisation (DNP) create non-Boltzmann population distribu-
tions across nuclear spin energy levels and can lead to MR
signal gains of up to five orders of magnitude.50 DNP can
achieve this effect in heteronuclei such as 89Y through transfer
of polarisation from unpaired electrons. This involves micro-
wave irradiation of a frozen glass matrix containing the 89Y
agent and a free radical in a magnetic field (B3 T) at low
temperature (1–2 K). This technique of transferring the inher-
ently greater electron polarisation to that of a proton was first
suggested by Albert Overhauser in 1953 and experimentally
validated by Carver and Slichter in the same year.50 It took until
2003 for dissolution DNP (d-DNP), which involves the rapid
melting of hyperpolarised solids with superheated solvent, to
offer a proven route to dramatically enhance the MR signals of
small molecules in solution.50 This breakthrough has created
the excitement needed to drive further development. Conse-
quently, d-DNP has now been used in a number of clinical
studies associated with the production of hyperpolarised 13C
tracers, of which pyruvate is the most widely reported.50 Indeed,
the in vivo injection and metabolic imaging of hyperpolarised
13C pyruvate into humans has been used as a method to
diagnose cancer.50
Despite the current successes of hyperpolarised 13C probes,
hyperpolarisation techniques can target many other hetero-
nuclei, including 89Y. 89Y is an interesting nucleus for study
by MR because it is non quadrupolar (I = 1/2) with 100% natural
abundance. As living cells have no known use for 89Y, there is
no inherent background response and consequently its use as a
medical probe provides an exciting opportunity for clinical
applications. However, one should note that 89Y has a gyro-
magnetic ratio that is around 20 times smaller than that of 1H
and its corresponding MR receptivity is 10 000 times smaller
than 1H, albeit similar to that of 13C. On the other hand, early
studies in the 1970s demonstrated that 89Y salts exhibit long T1
times that can exceed 100 seconds.13 The incorporation of 89Y
into metal complexes was found to elongate relaxation times
even further.13 Collectively, this makes Boltzmann polarised 89Y
MR studies challenging as low receptivity must be overcome by
signal averaging which necessitates long measurement times to
overcome the long relaxation lifetime. These measurement
times for thermally polarised samples can be reduced by the
addition of relaxation inducing dopants, which overcome
the latter effect. In contrast, long relaxation times provide the
potential to detect hyperpolarised 89Y nuclei in vivo before the
hyperpolarised state decays back to its Boltzmann populated
state and may provide many advantages. For example, DNP has
been used to successfully hyperpolarise 89Y with enhanced
89Y NMR signals detected in just a single scan (Table 5).13
Achieving this result is a substantial breakthrough as measure-
ment of Boltzmann derived signals is challenging for the
reasons given above and the DNP process is itself costly, time
consuming and single shot in nature. In addition, whilst most
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able to monitor 13C signal intensity as a function of microwave
frequency and subsequent signal growth over increasing
irradiation time, such systems are unable to monitor changes
in 89Y signals in a similar way. Therefore, finding the optimum
microwave frequency and irradiation time required for opti-
mum polarisation of 89Y nuclei is challenging and involves
the rapid melting and ejection of many separate samples
for the buildup and NMR detection of 89Y signal intensity.
These technical challenges are reflected in the range of different
89Y polarisation conditions reported in the literature to date
(Table 5).13,51–53
Optimisation of these polarisation conditions can include
modification of several factors including the organic radical
used for polarisation transfer, the glassing matrix, concentra-
tions, and irradiation time and frequency. Lumata et al. have
performed a detailed study of the effect of these factors on
89Y signal gains.51 It was reported that using organic radicals
with narrow electron paramagnetic resonance linewidths (such
as trityl rather than nitroxyl radicals) yields more efficient
polarisation transfer from the unpaired electron to the 89Y
target of interest.51 Moreover, addition of an electron relaxing
agent such as a Gd3+ salt can yield higher 89Y polarisation by up
to a factor of five (Fig. 9a).51 This effect has been reported for
other heteronuclei such as 13C. Performing these optimisation
steps is time consuming and challenging as 89Y signal growth
cannot be monitored in situ, as previously discussed. For
example, optimisation of polarising frequency and irradiation
time involved d-DNP of 12 and 7 separate 89Y-DOTA samples
respectively.51 Despite these challenges, by combination of
various optimisation steps, including using optimum micro-
wave frequencies, irradiation times, radical, Gd3+ additive and
viscous glass forming solvents, 89Y signals enhanced by a factor
of 65 000 were achieved.51
Interestingly, the co-polarisation of sodium pyruvate-1-13C
or polarisation of 13C-enriched 89Y-DOTA has been used to
provide information on the mechanism of signal enhancement.
In these systems the growth of 13C polarisation can be mon-
itored in situ and this is correlated to the 89Y signal gain
(Fig. 9b).51,52 The co-polarisation of 89Y and 13C nuclei may
provide a way to indirectly monitor the growth of 89Y polarisa-
tion and reliably predict the 89Y signal gain upon rapid melting
and ejection of the sample.
The hyperpolarisation of a wide range of yttrium containing
complexes has been reported using d-DNP (Fig. 9c and
Table 5).11,53 These examples show that 89Y chemical shift is
highly dependent on its coordination environment with large
(B80 ppm) shift differences reported for hyperpolarised 89Y
nuclei coordinated to various different macrocyclic ligands.
Such high sensitivity of 89Y chemical shift to molecular environ-
ment has been exploited to design hyperpolarised 89Y pH
Fig. 9 Applications of hyperpolarised 89Y complexes in MR. (a) Example polarisation buildup curves of 0.28 M Y-DOTA samples in a 1 : 1 glycerol/water
glassing matrix doped with 15 mM trityl radical and Gd3+ (0, 2.5, and 10 mM). (b) Polarisation buildup of samples with 1-13C pyruvate (left axis) and
89Y-DOTA (right axis) doped with 15 mM trityl OX063 and 2.5 mM Gd3+ at 1.4 K and 3.35 T. Note that each data point in the 89Y buildup curves in (a) and
(b) represents a separate DNP experiment. (c) 89Y NMR spectra collected at 29.4 MHz using a 14.1 T magnet of hyperpolarised yttrium complexes
recorded with a 101 excitation pulseB30 s after transfer from the DNP polariser to a 8 mm NMR tube. (d) 89Y chemical shift dispersion of hyperpolarised
Y-DOTP and YDO3A-NTs as a function of pH (9.4 T and 25 1C) and the corresponding structures of their ligands. (e) Y-DOTA hyperpolarised using DNP
has been injected and imaged in a rat kidney. Reproduced with permission from (a) and (b) ref. 51. Copyright r 2011 American Chemical Society (c)
ref. 53. Copyright r 2007 American Chemical Society (d) ref. 54. Copyright r 2010 American Chemical Society and (e) ref. 55. Copyright r 2010
International Society for Magnetic Resonance in Medicine.
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sensitive probes. Examples contain phosphonate and carbox-
ylate groups, whose protonation state changes with pH, thereby
affecting the molecular environment around the coordinated
89Y ion and its subsequent chemical shift (Fig. 9d).54 Other
studies have utilised the differences in hyperpolarised
89Y chemical shift that exist between free and complexed ions
to measure complexation rates to the macrocyclic DOTAM
ligand and the associated binding kinetics.17
It was not until 2016 that a quantitative link between 89Y
chemical shift and environment was outlined through studies
on 23 complexes containing polyaminocarboxylate ligands.
In this seminal work, an empirical equation was derived to
accurately relate 89Y chemical shift to the number and type of
coordinating atoms.13 Good agreement was found between
89Y shifts predicted from this empirical equation and those
observed for both thermal and hyperpolarised samples. Hyper-
polarised 89Y studies can therefore provide important informa-
tion on complex kinetics and protonation states. It should also
be noted that typical concentrations of 89Y complexes detected
in vitro in single scan hyperpolarised NMR spectra lie in the
range 100 mM–7 mM, which are significantly higher than those
which feature as PET tracers (see above). We are not aware of
any detection limit for 89Y HP-MRI, but note that this can be
improved by future development of experimental set up, RF coil
detection, and increased 89Y signal gains.
Research into the hyperpolarisation of 89Y is currently at the
level of preliminary in vivo imaging studies. In an initial report,
Y-DOTA was administered in a rat kidney to provide the first
89Y MR images (Fig. 9e);55 further examples in this direction are
still pending. However, 89Y chemical shift has proven to be
highly sensitive to the molecular environment and it is
expected that future uses of 89Y as a probe for such changes
in molecular environment can be envisaged. It has already been
shown that 89Y chemical shift of Y-EDTA can change by as
much as B10 ppm in the presence of sodium lactate at pH 6.4
and 25 1C at 9.4 T.13 Therefore, 89Y complexes may serve a
unique role as an in vivo probe for such biomolecules. Currently,
DNP is a time consuming and expensive technique available only to
a few research institutions. While no reports of 89Y hyperpolarised
with techniques other than DNP have been reported, advances in
other hyperpolarisation techniques including the cheaper para-
hydrogen based methods50 may reflect exciting opportunities to
target the hyperpolarisation of 89Y.
Conclusions
The role of yttrium in medical applications, especially radio-
therapy and medical imaging, has been frequently neglected.
Yttrium can form a large number of complexes owing to its
specific coordination and radiochemical properties which show
a wide variety of features. To this end, yttrium complexes can
provide a route to multimodal imaging in which the same
ligands can be coordinated to 86Y and used for PET, 90Y and
used for radiotherapy, and 89Y and used for HP-MRI, with
89Y chemical shifts extremely sensitive to molecular environment.
The former two methods have already found a number of
applications in modern medical diagnostic and therapeutic
procedures, which are briefly overviewed in this work. None-
theless, owing to its versatile properties, yttrium’s mostly
abundant isotope 89Y possesses properties suitable for NMR
and MRI applications. Combined with hyperpolarisation, an
emerging technique in modern NMR, yttrium offers a whole
new avenue for molecular imaging studies based on metal
chelates. All these methods together highlight the substantial
contribution that yttrium has had, and will have, to biomedical
research and clinical routines towards improving human
health. With the most recent advances, the palette of its
applications is expanding and further exciting progress is

















DO3A-NTs A DO3A derived ligand whose structure is












EDTMP Ethylenediamine tetra(methylene phosphonic
acid)
EGFR Epidermal growth factor receptors
18FDG Fluorodeoxyglucose (18F)
HER2 A human epidermal growth factor receptors
HILIC-ICP-MS Hydrophilic interaction chromatography and
inductively coupled plasma mass spectrometry
HP-MRI Hyperpolarised magnetic resonance imaging
LNCaP Androgen sensitive human prostate adeno-
carcinoma cell line
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PET Positron emission tomography
PRRT Peptide receptor radionuclide therapy
ReCCMSH A cyclic analogue of a-melanocyte stimulating
hormone
RF Radiofrequency
SAP Monocapped square antiprism
SEM Scanning electron microscope
SPECT Single-photon emission CT
TEMPO (2,2,6,6-Tetramethylpiperidin-1-yl)oxyl or (2,2,6,6-
tetramethylpiperidin-1-yl)oxidanyl
TSAP Monocapped twisted square antiprism
TTP Tricapped trigonal prism
VEGF-A Vascular endothelial growth factor A
YAG Yttrium aluminium garnet
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